These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

32 related articles for article (PubMed ID: 9183940)

  • 1. [The future of antiviral drugs].
    Moutouh L; Calvez V; Huraux JM
    Rev Prat; 1997 Mar; 47(6):652-7. PubMed ID: 9183940
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antiviral chemotherapy in pediatrics--its present and prospects].
    Arion C; Zamfirescu A; Popescu V
    Pediatrie (Bucur); 1992; 41(1):46-52. PubMed ID: 1322725
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiviral therapy: current options and challenges.
    Reusser P
    Schweiz Med Wochenschr; 2000 Jan; 130(4):101-12. PubMed ID: 10780051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of novel strategies to combat hepatitis B virus targetting wild-type and drug-resistant mutants in experimental models.
    Zoulim F
    Antivir Chem Chemother; 2001; 12 Suppl 1():131-42. PubMed ID: 11594680
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of viral drug resistance by novel combination therapy.
    Mangel WF; Brown MT; Baniecki ML; Barnard D; McGrath WJ
    Curr Opin Investig Drugs; 2001 May; 2(5):613-6. PubMed ID: 11569932
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Major causes of antiviral drug resistance and implications for treatment of hepatitis B virus monoinfection and coinfection with HIV.
    Locarnini S; Warner N
    Antivir Ther; 2007; 12 Suppl 3():H15-23. PubMed ID: 18284179
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiviral resistance and impact on viral replication capacity: evolution of viruses under antiviral pressure occurs in three phases.
    Nijhuis M; van Maarseveen NM; Boucher CA
    Handb Exp Pharmacol; 2009; (189):299-320. PubMed ID: 19048205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multi-target spectral moment: QSAR for antiviral drugs vs. different viral species.
    Prado-Prado FJ; Borges F; Uriarte E; Peréz-Montoto LG; González-Díaz H
    Anal Chim Acta; 2009 Oct; 651(2):159-64. PubMed ID: 19782806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral drug resistance.
    Richman DD
    Antiviral Res; 2006 Sep; 71(2-3):117-21. PubMed ID: 16621040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glucosidase inhibitors as antiviral agents for hepatitis B and C.
    Durantel D; Alotte C; Zoulim F
    Curr Opin Investig Drugs; 2007 Feb; 8(2):125-9. PubMed ID: 17328228
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiviral drugs in influenza: an adjunct to vaccination in some situations.
    Prescrire Int; 2006 Feb; 15(81):21-30. PubMed ID: 16548114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The priorities for antiviral drug resistance surveillance and research.
    Pillay D
    J Antimicrob Chemother; 2007 Aug; 60 Suppl 1():i57-8. PubMed ID: 17656384
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutations of neuraminidase implicated in neuraminidase inhibitors resistance.
    Ferraris O; Lina B
    J Clin Virol; 2008 Jan; 41(1):13-9. PubMed ID: 18055254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Future perspectives and strategies in managing resistance to analogue antiviral drugs in the treatment of chronic hepatitis B].
    Bourlière M
    Gastroenterol Clin Biol; 2006 Oct; 30(10 Pt 2):3S34-6. PubMed ID: 17075495
    [No Abstract]   [Full Text] [Related]  

  • 16. Hepatitis B virus mutations associated with antiviral therapy.
    Bartholomeusz A; Locarnini S
    J Med Virol; 2006; 78 Suppl 1():S52-5. PubMed ID: 16622878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human cytomegalovirus resistance to antiviral drugs: diagnosis, monitoring and clinical impact.
    Baldanti F; Gerna G
    J Antimicrob Chemother; 2003 Sep; 52(3):324-30. PubMed ID: 12888590
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hepatitis B virus escape mutants induced by antiviral therapy.
    Sheldon J; Soriano V
    J Antimicrob Chemother; 2008 Apr; 61(4):766-8. PubMed ID: 18218641
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular proteins (cyclin dependent kinases) as potential targets for antiviral drugs.
    Schang LM
    Antivir Chem Chemother; 2001; 12 Suppl 1():157-78. PubMed ID: 11594683
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiviral therapy of chronic hepatitis B: prevention of drug resistance.
    Fournier C; Zoulim F
    Clin Liver Dis; 2007 Nov; 11(4):869-92, ix. PubMed ID: 17981233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 2.